A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

NCT06633783 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide injection works as well as Wegovy® to help people with obesity lose weight.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 370 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2024-10 · est. completion 2026-10

Where 14 sites · China

What this study is testing ClinicalTrials.gov NCT06633783 ↗

Description as written by the study sponsor.

The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.

Semaglutide Drug

The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.
Semaglutide Drug

The dose escalation phase, starting with 0.25mg once weekly and increasing every 4 weeks (0.5mg, 1.0mg, 1.7mg), is expected to last 16 weeks; In the dose maintenance phase, the target dose of 2.4mg was maintained for 28 weeks.Treatment duration 44 weeks.

Main thing measured	Change in body weight
Sponsor	Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06633783 ↗